DEPAKOTE

This brand name is authorized in United States. It is also authorized in Brazil, France, UK.

Active ingredients

The drug DEPAKOTE contains one active pharmaceutical ingredient (API):

1	Divalproex sodium UNII 644VL95AO6 - DIVALPROEX SODIUM
	Valproic acid is anti-convulsant. The most likely mode of action for valproate is potentiation of the inhibitory action of gamma amino butyric acid (GABA) through an action on the further synthesis or further metabolism of GABA.
	Read more about Valproic acid

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DEPAKOTE Delayed-release tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
DEPAKOTE SPRINKLES Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05AX	Other antipsychotics	N Nervous system → N05 Psycholeptics → N05A Antipsychotics
Discover more medicines within N05AX

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	500202503110318, 500202504117316, 500202601112315, 500202603115311, 500209002117317, 500209003113315, 500209004111316, 500209005116311, 500216120035503, 500216120035603
FR	Base de données publique des médicaments	60797287, 66508736
GB	Medicines & Healthcare Products Regulatory Agency	364429, 364431, 374027, 378888, 380773, 381277, 381279, 381280
US	FDA, National Drug Code	0074-3826, 0074-6114, 0074-6212, 0074-6214, 0074-6215, 0074-7126, 70518-1454, 70518-1456, 70518-1758, 70518-1759